Compare BSAC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | PCVX |
|---|---|---|
| Founded | 1977 | 2013 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0B | 6.1B |
| IPO Year | 2002 | 2020 |
| Metric | BSAC | PCVX |
|---|---|---|
| Price | $32.27 | $56.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $29.50 | ★ $98.33 |
| AVG Volume (30 Days) | 383.0K | ★ 1.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.86 | N/A |
| Revenue Next Year | $7.32 | N/A |
| P/E Ratio | $14.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.77 | $28.09 |
| 52 Week High | $37.72 | $73.82 |
| Indicator | BSAC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 50.96 |
| Support Level | $32.17 | $42.30 |
| Resistance Level | $33.36 | $58.95 |
| Average True Range (ATR) | 0.98 | 2.47 |
| MACD | 0.06 | -0.62 |
| Stochastic Oscillator | 70.47 | 37.09 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.